Loading stock data…
ANIX
$3.14+0.14 (+4.67%)
Market ClosedLast close May 1
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anixa Biosciences, Inc. in the Healthcare sector is trading at $3.14. The stock is currently 42% below its 52-week high of $5.46, remaining 6.8% below its 200-day moving average. Technical signals show neutral RSI of 61 and bullish MACD crossover, explaining why ANIX maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.14
Potential Upside
5%
Whystock Fair Value$3.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T ce...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$105.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-68.37%
Volume
Today's trading volume
158,530
Recent News
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference
Anixa Biosciences (NASDAQ:ANIX) CEO Dr. Amit Kumar outlined the company’s strategy for advancing two clinical-stage oncology programs while maintaining what he described as a “very modest” cash burn during a Water Tower Research conference session moderated by Robert Sassoon, Managing Director of He
Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress
Anixa Biosciences (NASDAQ:ANIX) held its 2026 Annual Meeting of Stockholders via live webcast, outlining the results of shareholder votes and providing an operational update focused on the company’s clinical-stage oncology pipeline and partnership-driven strategy. Annual meeting votes and quorum Pr
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance
Anixa Biosciences (NASDAQ:ANIX) Chairman and CEO Dr. Amit Kumar said the company views 2026 as a “pivotal year” as it advances two clinical-stage programs: a breast cancer vaccine being developed with the Cleveland Clinic and the U.S. Department of Defense, and a CAR-T cell therapy for terminally il
Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Top Penny Stocks To Watch In November 2025
The U.S. stock market has seen a downturn following the end of the longest federal shutdown in history, with major indices slipping as technology shares led declines. Despite these challenges, opportunities remain for investors willing to explore smaller or newer companies often categorized under the term "penny stocks." These stocks can offer significant growth potential at lower price points, especially when they are backed by strong financials and solid fundamentals.